Genomics informatics — Data elements and their metadata for describing the tumor mutation burden (TMB) information of clinical massive parallel DNA sequencing
Introduction: With the rapid advancement of next-generation sequencing (NGS) technologies, clinical sequencing has been applied to realize personalized and precision medicine. ISO/TS 20428[1] was published to standardize the clinical sequencing reports in electronic health records. After introducing NGS panel sequencings (whole genome, whole exome, targeted gene sequencing), they are widely used in the clinical field. In the field of cancer treatment, various treatment strategies were tried differently from traditional anti-cancer chemotherapies. Recently, drugs related to the immune system were developed and more efficient for patients with specific tumor molecular characteristics. It is the immune checkpoint blockade drug such as the first approved drug – Ipilimumab, an anti-cytotoxic T-lymphocyte antigen (CTLA4) for non-small cell lung cancer[2]. Tumors can use these checkpoints to protect themselves from immune system attacks. Currently approved checkpoint therapies block inhibitory checkpoint receptors. Blockade of negative feedback signaling to immune cells thus results in a continued immune response against tumors. It was reported that the status of Programmed Death-Ligand 1 (PD-L1) expression or the status of TMB (Tumor Mutation Burden) could be used as the predictive marker for the efficacy of the immune checkpoint blockade because TMB is considered an indirect measurement of how many tumor cell-specific peptide fragments are presenting and the increase of antigen-presenting leads
Scope: This document identifies data elements and metadata to represent the information about tumor mutation burden (TMB) when reporting the value for the biomarker using clinical massive parallel DNA sequencing. This document covers the TMB status and related metadata such as mutation type, sequencing types, and target areas of sequencing from human samples for clinical practice and research. This document is not intended — to define experimental protocols or methods for calculating the value of tumor mutation burden, — for the other biological species, and — for the Sanger sequencing methods.